Cypex Logo


We regularly share knowledge with industry publications and academic research projects.  The links below are to papers and posters that we feel will be useful in demonstrating the uses of our products.

Development of a fluorimetric assay for determining IC50 values with Bactosomes for 8 major human CYP isoforms; incorporation of IC50 value changes as a function of time to predict time/metabolism dependent inhibition.

C. Peet, A. Kaaz, M. Voice & M. Pritchard

Development of a fluorimetric assay to identify inhibitors of recombinant CYP2B6

C. Peet, A. Kaaz, M. Pritchard & M. Voice

Effect of solvent choice when performing fluorimetric IC50 assays with Bactosomes can influence the end result.

C. Peet, A. Kaaz, M. Voice & M. Pritchard

Recombinant Human CYPs are Stable when Stored Frozen in a Bulk Assay Premix.

Anna W. Kaaz, Caroline F. Peet, Michael P. Pritchard & Michael W. Voice

Effects of Using Different Assay Buffers on the Activity of Recombinant Human CYP3A4 Co-expressed in E. coli with Human NADPH P450 Reductase.

M. Voice

Effects of common organic solvents on the activity of recombinant human cytochrome P450s expressed in E. coli.

J. Baird, C. Begg, M. Pritchard & M. Voice

Cytochrome b5 Activation of CYP3A4 Activity is Buffer and Reductase Dependent.

G. Macintyre & M. Voice

Identifying a higher throughput assay for metabolism dependent inhibition (MDI).

M. Kajbaf, E. Palmieri & S. Fontana

DOI : 10.2174/187231210791292708

Evaluation of different approaches to identifying a higher throughput assay for time-dependent inhibition (TDI).

M. Kajbaf, R. Longhi & S. Fontana

DOI : 10.2174/187231211795305230

A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry.

M. Kajbaf, R. Longhi, D. Montanari, F. Vinco, M. Rigo, S. Fontana & K. Read

DOI : 10.2174/187231211794455262

The Development of a Cocktail CYP2B6, CYP2C8 and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting.

C. J. O'Donnell, K. Grime, P. Courtney, D. Slee & R. J. Riley


Automated Assessment of Time-Dependent Inhibition of Human Cytochrome P450 Enzymes Using Liquid Chromatography-Tandem Mass Spectrometry Analysis.

A. Atkinson, J. R. Kenny & K. Grime


Cytochrome P450 Inhibition Using Recombinant Proteins & Mass Spectroscopy/multiple Reaction Monitoring Technology in a Cassette Incubation.

R. Weaver, K. S. Graham, I. G. Beattie & R. J. Riley


A Method for the Simultaneous Evaluation of the Activities of Seven Major Human Drug-metabolising Cytochrome P450s Using an in vitro Cocktail of Probe Substrates and Fast Gradient Liquid Chromatography Tandem Mass Spectroscopy.

E. A. Dierks, K. R. Stams, H-K. Lim, G. Cornelius, H. Zhang & S. Ball

Development of Fluorogenic Assays for Determining IC50 Values for NCEs with a Panel of Canine Cytochrome P450s, Incorporating IC50 Changes Over Time to Predict Time / Metabolism Dependent Inhibition.

Voice M. W., Macintyre, G. M. M. & Pritchard, M. P.

Evaluation of Escherichia coli Membrane Preparations of Canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12 and 3A26 with Coexpressed Canine Cytochrome P450 Reductase.

C. W. Locuson, B. T. Ethell, M. W. Voice, D. Lee & K. L. Feenstra


Current Cytochrome P450 Phenotyping Methods Applied to Metabolic Drug-Drug Interaction Prediction in Dogs.

Beth Miskimins Mills, Matthew J. Zaya, Rodney R. Walters, Kenneth L. Feenstra,
Julie A. White, Jason Gagne, and Charles W. Locuson


Expression of four porcine CYPs in E. coli and development of fluorogenic CYP inhibition assays .

Voice M. W., Macintyre, G. M. M. & Pritchard, M. P.

Development of a Fast, Fluorescence Based Screen for Inhibition of B. tabaci, and T. urticae Cytochrome P450s.

Voice M. W., Macintyre, G. M. M. & Pritchard, M. P.

Recombinant CYP6M2 Inhibition by Insecticides Recommended by WHO for Indoor Residual Spraying.

Michael W. Voice, Anna W. Kaaz, Caroline F. Peet & Mark J. Paine

Pyriproxyfen is metabolized by P450s associated with pyrethroid resistance in An. gambiae

Cristina Yunta, Nelson Grisales, Szilard Nasz, Kay Hemmings, Patricia Pignatelli, Michael Voice, Hilary Ranson & Mark J.I. Paine


Enzymatic production of drug metabolites using recombinant human cytochrome P450s.

M. Voice

Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.

Butler CF, Peet C, Mason AE, Voice MW, Leys D, Munro AW.

DOI: 10.1074/jbc.M113.479717

Flavocytochrome P450 BM3 mutant W1046A is a NADH-dependent fatty acid hydroxylase: implications for the mechanism of electron transfer in the P450 BM3 dimer.

Girvan HM, Dunford AJ, Neeli R, Ekanem IS, Waltham TN, Joyce MG, Leys D, Curtis RA, Williams P, Fisher K, Voice MW, Munro AW.

DOI: 10.1016/

Human P450-like oxidation of diverse proton pump inhibitor drugs by ‘gatekeeper’ mutants of flavocytochrome P450 BM3.

Christopher F. Butler, Caroline Peet, Kirsty J. McLean, Michael T. Baynham, Richard T. Blankley, Karl Fisher, Stephen E. J. Rigby, David Leys, Michael W. Voice, Andrew W. Munro

DOI: 10.1042/BJ20140030

Novel insights into P450 BM3 interactions with FDA-approved antifungal azole drugs

Laura N. Jeffreys, Harshwardhan Poddar, Marina Golovanova, Colin W. Levy, Hazel M. Girvan, Kirsty J. McLean, Michael W. Voice, David Leys & Andrew W. Munro

DOI: 10.1038/s41598-018-37330-y

Latest Blogs